Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Ciprofloxacin + fluocinolone acetonide** is a fixed-dose otic antibacterial and corticosteroid combination. Ciprofloxacin is a fluoroquinolone that inhibits bacterial DNA gyrase and topoisomerase IV, causing bactericidal disruption of bacterial DNA replication. Fluocinolone acetonide is a glucocorticoid receptor agonist that suppresses local inflammatory signaling. The combination is supplied as a 0.3%/0.025% otic solution, including brands such as Otovel and Cetraxal Plus, for bacterial ear infections including acute otitis media with tympanostomy tubes and, in certain markets, acute otitis externa.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on ciprofloxacin + fluocinolone acetonide.